Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.
The U.S. Food and Drug Administration rejected Orphazyme’s key drug candidate for Niemann-Pick disease type C (NPC), causing the Denmark-based biopharmaceutical company’s “meme stock” to decline in trading.
Orphazyme’s Rare Lipid Disorder Drug Gets FDA Priority Review
Accepted NDA, Clinical Data, Clinical Trials, Fast Track Designation, FDA, FDA/Regulatory, Heat-Shock Proteins (HSPs), Lipid disorders, Niemann-Pick C Disease (NPC), Primary Endpoints, Priority Review Status, R&D, Rare Genetic Diseases, Secondary EndpointsThe U.S. Food and Drug Administration accepted Copenhagen, Denmark-based Orphazyme’s New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick disease Type C.